AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22631032 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 81 mg
Number of subjects: 29
Study 22631032 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 81 mg + esomeprazole 20 mg
Number of subjects: 29
Study 22631032 — intervention group
Group type: COMPARATOR
Intervention: ASA + esomeprazole
Number of subjects: 29
Study 19553142 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-20 mg once per day for 12 weeks)
Number of subjects: 70
Study 19553142 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy persons)
Number of subjects: 70
Study 19553142 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (20 type 2 diabetic patients without nephropathy)
Number of subjects: 70
Study 19553142 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (20 type 2 diabetic patients with nephropathy)
Number of subjects: 70
Study 17643340 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilaterally applied postero‐anterior mobilisation to the left L4/5 zygopophyseal joint
Number of subjects: 45
Study 17643340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17643340 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 16619571 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral pilocarpine 3 times a day during radiotherapy for 12 weeks
Number of subjects: 66
Study 16619571 — intervention group
Group type: COMPARATOR
Intervention: Control group received pilocarpine only in the second 6 weeks following irradiation
Number of subjects: 66
Study 12832683 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 36
Study 12832683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10781275 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 10781275 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus alfentanil 100 ng/ml
Number of subjects: 20
Study 10781275 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 20
Study 10781275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pa and Nb latencies
Number of subjects: 20
Study 8896009 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan needle
Number of subjects: 388
Study 8896009 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge Quincke needle
Number of subjects: 388
Study 1683252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 1683252 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 0
Study 1683252 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 0
Study 1683252 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 0
Study 1683252 — intervention group
Group type: COMPARATOR
Intervention: Codeine
Number of subjects: 0
Study 1683252 — intervention group
Group type: COMPARATOR
Intervention: Antigen
Number of subjects: 0
Study 6355247 — intervention group
Group type: EXPERIMENTAL
Intervention: IPG (immunotherapy with polymerized whole grass)
Number of subjects: 26
Study 6355247 — intervention group
Group type: COMPARATOR
Intervention: Caramelized glucose histamine placebo
Number of subjects: 26
Study 31218545 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-stigma intervention
Number of subjects: 0
Study 30583732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen
Number of subjects: 0
Study 30583732 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27075909 — intervention group
Group type: EXPERIMENTAL
Intervention: LD + MCT (l‐leucine 1.2 g, cholecalciferol 20 μg, 6 g medium‐chain triglycerides)
Number of subjects: 38
Study 27075909 — intervention group
Group type: COMPARATOR
Intervention: LD + LCT (l‐leucine 1.2 g, cholecalciferol 20 μg, 6 g long‐chain triglycerides)
Number of subjects: 38
Study 27075909 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 38
Study 25204676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutrition intervention (eight visits with a renal dietitian over the first six months, four visits over the second six months, and three visits over the first six months with an exercise physiologist)
Number of subjects: 0
Study 25204676 — intervention group
Group type: COMPARATOR
Intervention: Standard care (four visits with a renal dietitian over twelve months)
Number of subjects: 0
Study 22080632 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐esterase inhibitor infusion (12,000 U) in addition to conventional treatment
Number of subjects: 61
Study 22080632 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only (control group)
Number of subjects: 61
Study 22080632 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐esterase inhibitor infusion
Number of subjects: 61
Study 19535971 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg/amlodipine 2.5 mg
Number of subjects: 190
Study 19535971 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/amlodipine 5 mg
Number of subjects: 190
Study 19535971 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 25 mg alone
Number of subjects: 190
Study 19535971 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg alone
Number of subjects: 190
Study 19535971 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol/amlodipine combination
Number of subjects: 190
Study 17216399 — intervention group
Group type: EXPERIMENTAL
Intervention: Farabloc (F)
Number of subjects: 67
Study 17216399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 67
Study 17216399 — intervention group
Group type: EXPERIMENTAL
Intervention: P/F (phase 2)
Number of subjects: 67
Study 17216399 — intervention group
Group type: EXPERIMENTAL
Intervention: F/P (phase 2)
Number of subjects: 67
Study 17216399 — intervention group
Group type: EXPERIMENTAL
Intervention: P/P (phase 2)
Number of subjects: 67
Study 15872126 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plaster (1 x 1 cm) affixed at the P6 acupoint 30 min before induction of anesthesia
Number of subjects: 120
Study 15872126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg iv given at the end of surgery
Number of subjects: 120
Study 15872126 — intervention group
Group type: COMPARATOR
Intervention: Inactive adhesive plaster (control group)
Number of subjects: 120
Study 12566894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour paclitaxel infusion
Number of subjects: 25
Study 12566894 — intervention group
Group type: COMPARATOR
Intervention: 3-hour paclitaxel infusion
Number of subjects: 25
Study 10847872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual visits and feedback by peers
Number of subjects: 90
Study 10847872 — intervention group
Group type: COMPARATOR
Intervention: Visits and feedback by non-physician observers
Number of subjects: 90
Study 8664454 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg BN52021 (paf-receptor antagonist) injected twice just before vascular cannulation and before cross-clamp release
Number of subjects: 18
Study 8664454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2363546 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg.kg‐1 propofol
Number of subjects: 60
Study 2363546 — intervention group
Group type: COMPARATOR
Intervention: 3 mg.kg‐1 propofol + 1.5 mg.kg‐1 suxamethonium
Number of subjects: 60
Study 369925 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaprozin 600 mg/day
Number of subjects: 212
Study 369925 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaprozin 1200 mg/day
Number of subjects: 212
Study 369925 — intervention group
Group type: COMPARATOR
Intervention: aspirin 3900 mg/day
Number of subjects: 212
Study 29609032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 73
Study 29609032 — intervention group
Group type: COMPARATOR
Intervention: Excision
Number of subjects: 73
Study 27660329 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 27
Study 25963394 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing treatments focusing on trauma, sexuality, or daily life (control condition)
Number of subjects: 136
Study 23445916 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise (VIB)
Number of subjects: 68
Study 23445916 — intervention group
Group type: COMPARATOR
Intervention: Balance training (BAL)
Number of subjects: 68
Study 20690878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load activities (LLA+) post-surgery (n=21)
Number of subjects: 38
Study 20690878 — intervention group
Group type: COMPARATOR
Intervention: Low-load activities (LLA-) post-surgery (n=17)
Number of subjects: 38
Study 19742342 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycosides of Tripterygium wilfordii (GTW)
Number of subjects: 45
Study 19742342 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 45
Study 16410202 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care model (intervention group)
Number of subjects: 80
Study 16410202 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 80
Study 15041597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (bolus injection of 1.5 mg/kg in 10 min followed by an IV infusion of 1.5 mg/kg/h)
Number of subjects: 40
Study 15041597 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 11765119 — intervention group
Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors
Number of subjects: 0
Study 11765119 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric use of GP IIb/IIIa inhibitors
Number of subjects: 0
Study 8998092 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diltiazem
Number of subjects: 30
Study 8998092 — intervention group
Group type: COMPARATOR
Intervention: i.v. digoxin
Number of subjects: 30
Study 8998092 — intervention group
Group type: COMPARATOR
Intervention: i.v. diltiazem and i.v. digoxin (combination)
Number of subjects: 30
Study 8343668 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits by public health nurses (four visits a year over three years)
Number of subjects: 580
Study 8343668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 580
Study 3539821 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg/day for 1 month
Number of subjects: 33
Study 3539821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3539821 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline and Placebo
Number of subjects: 33
Study 30744517 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Pulsed Electromagnetic Fields (active treatment)
Number of subjects: 97
Study 30744517 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 97
Study 27213785 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (LC) within three days after ERCP
Number of subjects: 56
Study 27213785 — intervention group
Group type: COMPARATOR
Intervention: Late laparoscopic cholecystectomy (LC) one month after ERCP
Number of subjects: 56
Study 24739486 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinization Technique (10% NaOCl for 1 min + Prime & Bond NT)
Number of subjects: 30
Study 24739486 — intervention group
Group type: COMPARATOR
Intervention: Conventional Technique (acid etching with 37% phosphoric acid + Prime & Bond NT)
Number of subjects: 30
Study 22447003 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic 80 beats/min IABP‐induced pulsatile CPB (Group B)
Number of subjects: 501
Study 22447003 — intervention group
Group type: COMPARATOR
Intervention: Linear cardiopulmonary bypass (Group A)
Number of subjects: 501
Study 20523050 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day (capsules bid)
Number of subjects: 541
Study 20523050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 18477074 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 20
Study 18477074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16006298 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of 12.5 microg of liothyronine (LT(3)) for 50 microg of levothyroxine (LT(4))
Number of subjects: 30
Study 16006298 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine (LT(4)) alone
Number of subjects: 30
Study 12865611 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced blood pressure elevation (treated patients, n = 9)
Number of subjects: 15
Study 12865611 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (untreated patients, n = 6)
Number of subjects: 15
Study 11063155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SPGI levels (< 25 microg/l) with diagnostic gastroscopy
Number of subjects: 1344
Study 11063155 — intervention group
Group type: COMPARATOR
Intervention: Control group with SPGI >= 50 microg/l
Number of subjects: 1344
Study 11063155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SPGI levels with severe neoplastic lesions
Number of subjects: 1344
Study 11063155 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative treatment for early cancer or high-grade dysplasia
Number of subjects: 1344
Study 11063155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year survival rate among gastric cancer cases
Number of subjects: 1344
Study 9279143 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed formula (N)
Number of subjects: 155
Study 9279143 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed formula (PH)
Number of subjects: 155
Study 9279143 — intervention group
Group type: COMPARATOR
Intervention: Regular formula (RM)
Number of subjects: 155
Study 8290862 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask breathing through the mouth only (FM/mouth)
Number of subjects: 0
Study 8290862 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask breathing through the nose only (FM/nose)
Number of subjects: 0
Study 8290862 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece with nose-clip (MP+NC)
Number of subjects: 0
Study 2423800 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (50-100 mg/day)
Number of subjects: 60
Study 2423800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10-20 mg/day)
Number of subjects: 60
Study 29667449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Number of subjects: 32
Study 29667449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen liquid capsule
Number of subjects: 32
Study 29667449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium
Number of subjects: 32
Study 29667449 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen acid (reference)
Number of subjects: 32
Study 29667449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen salts (overall)
Number of subjects: 32
Study 26865445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 11623
Study 26865445 — intervention group
Group type: COMPARATOR
Intervention: Abciximab plus UFH
Number of subjects: 11623
Study 26865445 — intervention group
Group type: COMPARATOR
Intervention: UFH alone
Number of subjects: 11623
Study 24420549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal angiotensin II (400 μg)
Number of subjects: 16
Study 24420549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24085050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 0
Study 24085050 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 0
Study 20872550 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 20872550 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 20872550 — intervention group
Group type: COMPARATOR
Intervention: No concomitant treatment (Control)
Number of subjects: 0
Study 18194506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol 2 mg/kg
Number of subjects: 127
Study 18194506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol 5 mg/kg
Number of subjects: 127
Study 18194506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol 6.5 mg/kg
Number of subjects: 127
Study 18194506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol 8 mg/kg
Number of subjects: 127
Study 18194506 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.02 mg/kg
Number of subjects: 127
Study 17189550 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (AOX) treatment (800 IU of vitamin E, 500 mg of vitamin C, 10 mg of beta-carotene)
Number of subjects: 48
Study 17189550 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (AOX) treatment
Number of subjects: 48
Study 17189550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 48
Study 14586351 — intervention group
Group type: EXPERIMENTAL
Intervention: Grand multiparous women
Number of subjects: 0
Study 14586351 — intervention group
Group type: COMPARATOR
Intervention: Lower parity multiparous women
Number of subjects: 0
Study 14586351 — intervention group
Group type: COMPARATOR
Intervention: Nulliparous women
Number of subjects: 0
Study 10756219 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 18
Study 10756219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8823240 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 20 mg
Number of subjects: 103
Study 8823240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 29807257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute vinegar lavage (20 mL of vinegar in 1 L saline) every second day during each estrus period (n=4)
Number of subjects: 8
Study 29807257 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=4)
Number of subjects: 8
Study 27578134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen treatment
Number of subjects: 64
Study 25641909 — intervention group
Group type: EXPERIMENTAL
Intervention: RESMENA diet (Mediterranean dietary pattern)
Number of subjects: 72
Study 25641909 — intervention group
Group type: COMPARATOR
Intervention: Control diet (American Heart Association guidelines)
Number of subjects: 72
Study 23013806 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Training and Assessment Curriculum (STAC)
Number of subjects: 20
Study 23013806 — intervention group
Group type: COMPARATOR
Intervention: Conventional residency training
Number of subjects: 20
Study 21964962 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking
Number of subjects: 1344
Study 21964962 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking with slow CYP2A6 genotype
Number of subjects: 1344
Study 21964962 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking with poor CYP2A6 genotype
Number of subjects: 1344
Study 18569272 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac gel applied once daily
Number of subjects: 49
Study 18569272 — intervention group
Group type: COMPARATOR
Intervention: 5% imiquimod cream applied three times a week for 12 weeks
Number of subjects: 49
Study 16048853 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, multifaceted depression treatment model
Number of subjects: 2
Study 16048853 — intervention group
Group type: COMPARATOR
Intervention: Geriatric Care Management Program
Number of subjects: 2
Study 11831837 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 20500
Study 11831837 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant vitamin cocktail (650 mg vitamin E, 250 mg vitamin C, 20 mg beta-carotene)
Number of subjects: 20500
Study 10051255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education for asthma (two 2-hour group sessions and one to two individual sessions by a nurse and physiotherapist)
Number of subjects: 140
Study 10051255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education for asthma
Number of subjects: 140
Study 10051255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no patient education)
Number of subjects: 140
Study 10051255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education for COPD
Number of subjects: 140
Study 8559480 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 50% or more cellular crescents
Number of subjects: 166
Study 8559480 — intervention group
Group type: EXPERIMENTAL
Intervention: Less extensive cellular crescents plus moderate to severe interstitial fibrosis
Number of subjects: 166
Study 8559480 — intervention group
Group type: EXPERIMENTAL
Intervention: Azotaemia, anaemia, hypocomplementaemia, hypertension, tubular atrophy, glomerular sclerosis
Number of subjects: 166
Study 8559480 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine, haematocrit, race, kidney pathology data
Number of subjects: 166
Study 1904198 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel
Number of subjects: 536
Study 1904198 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel
Number of subjects: 536
Study 1904198 — intervention group
Group type: COMPARATOR
Intervention: Both dosages of praziquantel
Number of subjects: 536
Study 7015172 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose subcutaneous heparin
Number of subjects: 0
Study 7015172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 0
Study 7015172 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin group
Number of subjects: 0
Study 29914300 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation with concurrent exposure
Number of subjects: 24
Study 29914300 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation with terminal exposure
Number of subjects: 24
Study 30374818 — intervention group
Group type: COMPARATOR
Intervention: 41.4 Gy (low-dose)
Number of subjects: 8881
Study 30374818 — intervention group
Group type: EXPERIMENTAL
Intervention: 50.4 Gy (high-dose)
Number of subjects: 8881
Study 30374818 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 Gy (moderate-dose)
Number of subjects: 8881
Study 28644907 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-fasting group (fasted until the day after ESD)
Number of subjects: 101
Study 28644907 — intervention group
Group type: COMPARATOR
Intervention: Long-fasting group (fasted until 2 days after ESD)
Number of subjects: 101